Skip to main content
    I

    Immunitybio Inc (IBRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.00
    +0.09 (+0.91%)

    Market Cap: $10.50B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(22/39)
    Avg Surprise
    -2.81%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.09 - $0.00
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.07+28.6%
    60d ago$-0.07+28.6%
    30d ago$-0.050.0%
    7d ago$-0.050.0%
    Current$-0.05
    Revenue Consensus
    $59M
    Range$56M - $66M
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.71
    Range$-0.73 - $-0.70
    2 analysts
    Revenue Consensus
    $73M
    Range$59M - $99M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.71---
    Sep 26EST
    		-$-0.05---
    Jun 26
    Reported Aug 4
    		$-0.08$-0.09+11.11%Beat+20.0%
    Mar 26
    Reported May 7
    		$-0.08$-0.07-14.29%Miss+46.7%
    Dec 25
    Reported Feb 23
    		$-0.06$-0.11+45.75%Beat+25.0%
    Sep 25
    Reported Nov 4
    		$-0.07$-0.10+30.00%Beat+41.7%
    Jun 25
    Reported Aug 5
    		$-0.10$-0.10+0.00%Beat+50.0%
    Mar 25
    Reported May 12
    		$-0.15$-0.16+6.25%Beat+25.0%
    Dec 24
    Reported Mar 3
    		$-0.08$-0.13+38.46%Beat+78.9%
    Sep 24
    Reported Nov 12
    		$-0.12$-0.18+33.33%Beat+36.8%
    Jun 24
    Reported Aug 12
    		$-0.20$-0.15-33.33%Miss+37.5%
    Mar 24
    Reported May 9
    		$-0.20$-0.16-25.00%Miss+25.9%
    Dec 23
    Reported Mar 19
    		$-0.38$-0.18-111.11%Miss-40.7%
    Sep 23
    Reported Nov 8
    		$-0.19$-0.18-5.56%Miss+32.1%
    Jun 23
    Reported Aug 8
    		$-0.32$-0.23-39.13%Miss-33.3%
    Mar 23
    Reported May 11
    		$-0.27$-0.27+0.00%Beat-3.8%
    Dec 22
    Reported Mar 1
    		$-0.27$-0.22-22.73%Miss-17.4%
    Sep 22
    Reported Nov 9
    		$-0.28$-0.21-33.33%Miss-27.3%
    Jun 22
    Reported Aug 8
    		$-0.24$-0.24+0.00%Beat-4.3%
    Mar 22
    Reported May 10
    		$-0.26$-0.22-18.18%Miss-23.8%
    Dec 21
    Reported Mar 1
    		$-0.23$-0.21-9.52%Miss+23.3%
    Sep 21
    Reported Nov 12
    		$-0.22$-0.20-10.00%Miss-10.0%
    Jun 21
    Reported Aug 12
    		$-0.23$-0.12-91.67%Miss-15.0%
    Mar 21
    Reported May 14
    		$-0.21$-0.41+48.78%Beat-10.5%
    Dec 20
    Reported Mar 4
    		$-0.30$-0.18-66.67%Miss-87.5%
    Sep 20
    Reported Nov 9
    		$-0.20$-0.18-11.11%Miss-25.0%
    Jun 20
    Reported Aug 7
    		$-0.20$-0.19-5.26%Miss-17.6%
    Mar 20
    Reported May 11
    		$-0.19$-0.17-11.76%Miss+13.6%
    Dec 19
    Reported Mar 25
    		$-0.16$-0.20+20.00%Beat+27.3%
    Sep 19
    Reported Nov 5
    		$-0.16$-0.18+11.11%Beat+46.7%
    Jun 19
    Reported Aug 6
    		$-0.17$-0.24+29.17%Beat+51.4%
    Mar 19
    Reported May 8
    		$-0.22$-0.23+4.35%Beat+37.1%
    Dec 18
    Reported Mar 13
    		$-0.22$-0.31+29.03%Beat+29.0%
    Sep 18
    Reported Nov 7
    		$-0.30$-0.37+18.92%Beat+0.0%
    Jun 18
    Reported Aug 6
    		$-0.35$-0.38+7.89%Beat-20.7%
    Mar 18
    Reported May 7
    		$-0.35$-0.34-2.94%Miss-16.7%
    Dec 17
    Reported Mar 12
    		$-0.31$-0.33+6.06%Beat-6.9%
    Sep 17
    Reported Nov 7
    		$-0.30$-0.32+6.25%Beat-
    Jun 17
    Reported Aug 7
    		$-0.29$-0.31+6.45%Beat-
    Mar 17
    Reported May 8
    		$-0.30$-0.36+16.67%Beat-
    Dec 16
    Reported Mar 15
    		$-0.29$-0.43+32.56%Beat-

    Key Metrics

    Valuation
    P/E Ratio-34.48EV/EBITDAN/A
    Price/FCF-36.40xFCF Yield-2.75%
    Profitability
    Profit Margin0.00%Operating Margin-120.40%
    ROE0.00%ROIC-576.27%
    Financial Health
    Debt/Equity-1.14xInterest Coverage-7.32x
    Current Ratio5.72xQuick Ratio5.70x
    Trading Statistics
    Beta0.03Avg Volume15.73M
    52-Week High$12.4352-Week Low$1.95

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.04
    SMA 20$9.42
    SMA 50$8.52
    SMA 200$7.56
    EMA 10$9.85
    EMA 20$9.48
    EMA 50$8.79
    EMA 200$7.26

    MACD

    Line: 0.48Signal: 0.47Hist: 0.01

    ADX

    ADX: 43.2+DI: 32.7-DI: 13.3

    Aroon & PSAR

    Aroon Up68.0
    Aroon DownN/A
    PSAR$10.73

    Bollinger Bands

    Upper Band$10.85
    Lower Band$7.99
    %B Position3035%(Upper)
    Band Width0.70

    RSI (14-Day)

    Neutral
    59.5

    Momentum Oscillators

    Stoch %K64.4
    Stoch %D68.1
    Williams %R-31.8
    ROC (10d)7.8%
    Momentum0.72
    CCI (20d)73.5
    MFI (14d)73.3

    Volatility Measures

    ATR (14d)$0.67(6.7%)
    StdDev (20d)0.71
    Hist Vol75.5%(High)

    Volume Flow

    VWAP$10.10
    OBV920.8M
    AD Line-203.6M
    CMF (20d)0.048

    Volume Metrics

    Avg Vol (20d)15.9M
    Vol Ratio1.3x
    VWMA (20d)$9.56

    Pivot Points

    R3$11.56
    R2$11.01
    R1$10.46
    Pivot Point$9.90
    S1$9.36
    S2$8.80
    S3$8.25

    Advanced Oscillators

    TSI22.35
    Ultimate Osc51.1
    KST211.82

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$51.24M$44.21M$64.71M$32.06M$26.43M$16.52M$8.60M$6.11M$0$40,000$139,000$82,000
    Cost of Revenue$298,000$238,000$69,000$354,000$136,000$58,000$4.14M$0$0$0$4.56M$0
    Gross Profit$50.94M$43.97M$64.64M$31.71M$26.29M$16.46M$8.60M$6.11M$0$40,000$139,000$82,000
    Operating Expenses$112.64M$113.76M$-82,502,000$175.03M$97.57M$80.89M$-109,787,000$172.72M$200.76M$95.24M$85.53M$80.22M
    R&D$60.82M$67.99M$-42,611,000$102.46M$55.24M$48.23M$-66,351,000$100.89M$102.26M$53.35M$51.53M$48.40M
    SG&A$51.82M$45.77M$-39,891,000$72.56M$42.34M$32.65M$-43,436,000$71.83M$98.50M$41.88M$33.11M$31.82M
    Operating Income$-61,697,000$-69,791,000$62.23M$-111,260,000$-71,285,000$-64,429,000$110.19M$-160,506,000$-198,666,000$-95,196,000$-85,389,000$-80,136,000
    Interest Income$3.15M$2.31M$-922,000$4.13M$1.15M$887,000$-2,502,000$3.60M$3.78M$3.10M$484,000$-1,220,000
    Interest Expense$31.24M$28.46M$-2,466,000$55.17M$28.88M$28.86M$-23,242,000$80.49M$59.59M$37.49M$32.13M$35.02M
    Income Before Tax$-230,390,000$-632,788,000$97.52M$-134,618,000$-92,305,000$-129,900,000$161.16M$-171,504,000$-269,168,000$-134,130,000$-233,454,000$-95,642,000
    Income Tax Expense$0$0$-404,000$-35,000$269,000$-234,000$0$0$0$0$-40,000$0
    Net Income$-230,390,000$-632,797,000$97.89M$-134,548,000$-92,574,000$-129,666,000$161.16M$-171,504,000$-269,168,000$-134,130,000$-233,414,000$-95,642,000
    EBITDA$-200,166,000$-603,784,000$68.99M$-78,273,000$-60,705,000$-98,145,000$131.09M$-84,532,000$-185,068,000$-90,129,000$-190,251,000$-43,378,000
    EBIT$-202,301,000$-606,638,000$66.83M$-81,246,000$-64,574,000$-101,922,000$121.97M$-94,606,000$-194,912,000$-99,742,000$-201,812,000$-59,401,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IBRX

    News

    Billionaire Patrick Soon-Shiong wins wider FDA approval for bladder cancer drug

    Billionaire Patrick Soon-Shiong's ImmunityBio Inc. received expanded FDA approval for its bladder cancer drug Anktiva...

    Billionaires.Africa•10/16/26•Bullish

    ImmunityBio (IBRX) Following ANKTIVA Label Expansion Still Looks Undervalued

    ImmunityBio (IBRX) is considered undervalued following the FDA's expanded label for its bladder cancer therapy ANKTIVA...

    Simply Wall Street•10/15/26•Bullish

    ImmunityBio Jumps as FDA Expands Anktiva Bladder Cancer Label to Majority of Patients

    The FDA has expanded the approved use of ImmunityBio's Anktiva to include adults with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with papillary-only tumors...

    finance.biggo.com•10/15/26•Bullish

    ANKTIVA + BCG Gains Expanded FDA Approval for BCG-Unresponsive NMIBC - ImmunityBio

    ImmunityBio, Inc. announced that the FDA has expanded the indication for ANKTIVA (nogapendekin alfa inbakicept-pmln) + BCG to include patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC)...

    Oncodaily•10/15/26•Bullish

    ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Gros

    Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ImmunityBio, Inc. (NASDAQ:IBRX) securities. The investigation focuses on whether ImmunityBio and its officers engaged...

    The National Law Review•10/15/26•Bearish

    IBRX Valuation and Fair Value

    P/E
    -34.5x
    Forward P/E
    123.5x
    P/FCF
    -36.4x
    P/B
    -10.0x
    See GNG's fair value

    IBRX Profitability: Margins, ROIC and FCF

    Gross margin
    99.5%
    Operating margin
    -120.4%
    Net margin
    0.0%
    ROIC
    -576.3%
    ROE
    0.0%
    FCF margin
    -150.1%
    FCF yield
    -2.7%

    IBRX Competitors

    CompanyTicker
    Oscar Health IncOSCR
    Madrigal Pharmaceuticals IncMDGL
    Dr. Reddy’s Laboratories Ltd ADRRDY
    Align Technology IncALGN
    Molina Healthcare IncMOH
    Globus MedicalGMED
    Universal Health Services IncUHS
    Apogee Therapeutics, Inc. Common StockAPGE

    Sector: Healthcare

    IBRX Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    1
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    IBRX Bull Case vs Bear Case

    Bull case

    • IBRX beat EPS estimates in 75.0% of its last 8 reported quarters.
    • IBRX grew quarterly revenue 93.9% year over year.

    IBRX Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    18.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.05
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About IBRX

    Does IBRX pay dividends?

    Immunitybio Inc (IBRX) does not currently pay a regular dividend.

    What is IBRX's market cap?

    Immunitybio Inc (IBRX) has a market capitalization of $10.50B with a current stock price of $10.00.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In